Overview
- Biohub unveiled a first-of-its-kind initiative combining frontier artificial intelligence with experimental biology to accelerate progress against disease.
- The EvolutionaryScale team will join the organization, and co-founder Alex Rives becomes head of science overseeing experimental biology, data and AI.
- New freely available tools include VariantFormer to translate personal genetic variants into tissue-specific gene activity, CryoLens for cryo-ET structural analysis, and scLDM for generating realistic single-cell data.
- A flagship Virtual Immune System program launches alongside four grand challenges covering a unified AI model of the cell, advanced imaging, real-time inflammation instrumentation, and AI-driven immune reprogramming.
- Zuckerberg and Chan said Biohub will ramp toward about $1 billion in annual funding over the next decade, building on roughly $4 billion already donated to basic science and their pledge to devote 99% of their wealth.